Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears IMDx Test for Flu, Respiratory Virus

NEW YORK (GenomeWeb News) – Molecular diagnostic firm IntelligentMDx today announced its flu and respiratory virus test has been cleared by the US Food and Drug Administration for marketing in the US.

The FDA cleared IMDx's automated molecular diagnostic test for the detection of influenza A, influenza B, and respiratory syncytial virus directly from nasopharyngeal swabs from patients who exhibit symptoms of respiratory infection. The test is for use on Abbott's automated m2000 platform.

Today's announcement follows FDA's clearance of IMDx's molecular diagnostic test for vancomycin-resistant enterococci in late July, also on the Abbott platform.

According to the Cambridge, Mass.-based firm, reactivity studies indicate that the IMDx Flu A/B and RSV assay can detect multiple influenza A/B and RSV strains from various geographical locations, such as H1N1, H3N2, and recently emergent H3N2 strains. The assay, the company said, can achieve results for up to 94 patient samples simultaneously.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.